CorePharm succeeds in avoiding Astellas’ patent by salt modification

While a series of domestic companies’ challenges to substance patents all went in vein after implementation of the Patent Linkage System on March 2015, a ruling was made in favor of a Korean challenger at the defensive confirmation trial for the scope of the substance patent of a urinary incontinence treatment which recently exceeds annual KRW 25 billion sales, ‘Vesicare Tab(generic name: solif...